Marco Migliore

Title: Marco Migliore: Innovator in Pharmaceutical Research

Introduction

Marco Migliore is a prominent inventor based in Genoa, Italy. He has made significant contributions to the field of pharmaceutical research, particularly in the development of innovative therapeutic agents. With a total of 2 patents, Migliore's work focuses on addressing critical health issues through novel chemical compounds.

Latest Patents

Migliore's latest patents include groundbreaking inventions aimed at modulating biological processes. One of his notable patents is for Piperazinyl methanone NAAA inhibitors. This invention discloses compositions and methods for modulating the activity of N-acylethanolamine acid amidase, which can be utilized for treating pathological states such as pain, inflammatory conditions, or neurodegenerative disorders. Another significant patent is for multitarget FAAH and COX inhibitors. This invention involves multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2). These inhibitors have a specific carbamate moiety and are designed for therapeutic applications, particularly in the prevention and treatment of cancer.

Career Highlights

Throughout his career, Marco Migliore has worked with esteemed institutions, including the University of California and the Fondazione Istituto Italiano Di Technologia. His research has been pivotal in advancing the understanding of enzyme inhibitors and their therapeutic potential.

Collaborations

Migliore has collaborated with notable researchers in his field, including Daniele Piomelli and Rita Scarpelli. These collaborations have enriched his research and contributed to the development of innovative therapeutic solutions.

Conclusion

Marco Migliore stands out as a key figure in pharmaceutical innovation, with his patents reflecting a commitment to addressing significant health challenges. His work continues to inspire advancements in therapeutic research and development.